DOCSLIB.ORG

Number 6 June 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Number 6 June 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology Volume 1 - Number 1 May - September 1997 Volume 20 - Number 6 June 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It is made for and by: clinicians and researchers in cytogenetics, molecular biology, oncology, haematology, and pathology. One main scope of the Atlas is to conjugate the scientific information provided by cytogenetics/molecular genetics to the clinical setting (diagnostics, prognostics and therapeutic design), another is to provide an encyclopedic knowledge in cancer genetics. The Atlas deals with cancer research and genomics. It is at the crossroads of research, virtual medical university (university and post-university e-learning), and telemedicine. It contributes to "meta-medicine", this mediation, using information technology, between the increasing amount of knowledge and the individual, having to use the information. Towards a personalized medicine of cancer. It presents structured review articles ("cards") on: 1- Genes, 2- Leukemias, 3- Solid tumors, 4- Cancer-prone diseases, and also 5- "Deep insights": more traditional review articles on the above subjects and on surrounding topics. It also present 6- Case reports in hematology and 7- Educational items in the various related topics for students in Medicine and in Sciences. The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. See also: http://documents.irevues.inist.fr/bitstream/handle/2042/56067/Scope.pdf Editorial correspondance Jean-Loup Huret, MD, PhD, Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France phone +33 5 49 44 45 46 [email protected] or [email protected] . Editor, Editorial Board and Publisher See:http://documents.irevues.inist.fr/bitstream/handle/2042/48485/Editor-editorial-board-and-publisher.pdf The Atlas of Genetics and Cytogenetics in Oncology and Haematology is published 12 times a year by ARMGHM, a non profit organisation, and by the INstitute for Scientific and Technical Information of the French National Center for Scientific Research (INIST-CNRS) since 2008. The Atlas is hosted by INIST-CNRS (http://www.inist.fr) Staff: Vanessa Le Berre Philippe Dessen is the Database Directorof the on-line version (Gustave Roussy Institute – Villejuif – France). Publisher Contact: INIST-CNRS Mailing Address: Catherine Morel, 2,Allée du Parc de Brabois, CS 10130, 54519 Vandoeuvre-lès-Nancy France. Email Address:[email protected] Articles of the ATLAS are free in PDF format, and metadata are available on the web in Dublin Core XML format and freely harvestable.A Digital object identifier (DOI®), recorded at the International Agency CrossRefhttp://www.crossref.org/ is assigned to each article. http://AtlasGeneticsOncology.org © ATLAS - ISSN 1768-3262 The PDF version of the Atlas of Genetics and Cytogenetics in Oncology and Haematology is a reissue of the original articles published in collaboration with the Institute for Scientific and Technical Information (INstitut de l’Information Scientifique et Technique - INIST) of the French National Center for Scientific Research (CNRS) on its electronic publishing platform I-Revues. Online and PDF versions of the Atlas of Genetics and Cytogenetics in Oncology and Haematology are hosted by INIST-CNRS. Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Editor-in-Chief Jean-Loup Huret (Poitiers, France) Lymphomas Section Editor Antonino Carbone (Aviano, Italy) Myeloid Malignancies Section Editor Robert S. Ohgami (Stanford, California) Bone Tumors Section Editor Judith Bovee (Leiden, Netherlands) Head and Neck Tumors Section Editors Cécile Badoual and Hélène Blons (Paris, France) Urinary Tumors Section Editor Paola Dal Cin (Boston, Massachusetts) Pediatric Tumors Section Editor Frederic G. Barr (Bethesda, Maryland) Cancer Prone Diseases Section Editor Gaia Roversi (Milano, Italy) AKT signalings Section Editor Robin C.Muise-Helmericks (Charleston, South Carolina) Cell Cycle Section Editor João Agostinho Machado-Neto (São Paulo, Brazil) DNA Repair Section Editor Godefridus Peters (Amsterdam, Netherlands) Hormones and Growth factors Section Editor Gajanan V. Sherbet (Newcastle upon Tyne, UK) Mitosis Section Editor Patrizia Lavia (Rome, Italy) WNT pathway Section Editor Alessandro Beghini (Milano, Italy) Board Members Sreeparna Department of Biological Sciences, Middle East Technical University, Ankara, Turkey; [email protected] Banerjee Alessandro Department of Health Sciences, University of Milan, Italy; [email protected] Beghini Judith Bovée 2300 RC Leiden, The Netherlands; [email protected] Dipartimento di ScienzeMediche, Sezione di Ematologia e Reumatologia Via Aldo Moro 8, 44124 - Ferrara, Italy; Antonio Cuneo [email protected] Paola Dal Cin Department of Pathology, Brigham, Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; [email protected] François IRBA, Departement Effets Biologiques des Rayonnements, Laboratoire de Dosimetrie Biologique des Irradiations, Dewoitine C212, Desangles 91223 Bretigny-sur-Orge, France; [email protected] Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, Roosevelt Dr. Oxford, OX37BN, UK Enric Domingo [email protected] Ayse Elif Erson- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey; [email protected] Bensan Ad Geurts van Department of Human Genetics, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6500 HB Kessel Nijmegen, The Netherlands; [email protected] Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University Vienna, Children's Cancer Oskar A. Haas Research Institute Vienna, Vienna, Austria. [email protected] Anne Hagemeijer Center for Human Genetics, University Hospital Leuven and KU Leuven, Leuven, Belgium; [email protected] Department of Pathology, The Ohio State University, 129 Hamilton Hall, 1645 Neil Ave, Columbus, OH 43210, USA; Nyla Heerema [email protected] Sakari Knuutila Hartmann Institute and HUSLab, University of Helsinki, Department of Pathology, Helsinki, Finland; [email protected] Lidia Larizza Lab Centro di Ricerche e TecnologieBiomedicheIRCCS-IstitutoAuxologico Italiano Milano, Italy; l.larizza@auxologico Department of Human, Animal Cell Lines, Leibniz-Institute DSMZ-German Collection of Microorganisms, Cell Cultures, Roderick Mc Leod Braunschweig, Germany; [email protected] Cristina Mecucci Hematology University of Perugia, University Hospital S.Mariadella Misericordia, Perugia, Italy; [email protected] Department of Clinical Genetics, University and Regional Laboratories, Lund University, SE-221 85 Lund, Sweden; Fredrik Mertens [email protected] Konstantin Miller Institute of Human Genetics, Hannover Medical School, 30623 Hannover, Germany; [email protected] Department of Clinical Genetics, University and Regional Laboratories, Lund University, SE-221 85 Lund, Sweden; Felix Mitelman [email protected] Hossain Mossafa Laboratoire CERBA, 95066 Cergy-Pontoise cedex 9, France; [email protected] Department of Human, Animal Cell Lines, Leibniz-Institute DSMZ-German Collection of Microorganisms, Cell Cultures, Stefan Nagel Braunschweig, Germany; [email protected] Florence Laboratory of Solid Tumors Genetics, Nice University Hospital, CNRSUMR 7284/INSERMU1081, France; Pedeutour [email protected] Department of Pathology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 250, Memphis, Tennessee Susana Raimondi 38105-3678, USA; [email protected] Clelia Tiziana Department of Biology, University of Bari, Bari, Italy; [email protected] Storlazzi Sabine Strehl CCRI, Children's Cancer Research Institute, St. Anna Kinderkrebsforschunge.V., Vienna, Austria; [email protected] Nancy Uhrhammer Laboratoire Diagnostic Génétique et Moléculaire, Centre Jean Perrin, Clermont-Ferrand, France; [email protected] Dan L. Van Dyke Mayo Clinic Cytogenetics Laboratory, 200 First St SW, Rochester MN 55905, USA; [email protected] Universita di Cagliari, Dipartimento di ScienzeBiomediche(DiSB), CittadellaUniversitaria, 09042 Monserrato (CA) - Italy; Roberta Vanni [email protected] Service d'Histologie-Embryologie-Cytogénétique, Unité de Cytogénétique Onco-Hématologique, Hôpital Universitaire Necker-Enfants Franck Viguié Malades, 75015 Paris, France; [email protected] Atlas Genet Cytogenet Oncol Haematol. 2016; 20(6) Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Volume 20, Number 6, June 2016 Table of contents Gene Section CDC25A (Cell division cycle 25A) 316 Christine Dozier, Stéphane Manenti MIR200A (microRNA 200a) 322 Yaguang Xi, Hong Chang MIR429 (microRNA 429) 324 Yaguang Xi, Hong Chang SH3PXD2A (SH3 and PX domains 2A) 326 Carman Man-Chung Li, Tyler Jacks SLPI (secretory leukocyte peptidase inhibitor) 331 Nella Ambrosi, Diego Guerrieri, Fiorella Caro, Micaela Barbieri Kennedy, Francisco Sánchez, Mercedes L. Sánchez, Eduardo Chuluyan SOCS2 (suppressor of cytokine signaling 2) 341 Indranil Paul, Leandro Fernández-Pérez, Amilcar Flores-Morales
Load more

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-Like Mouse Models: Tracking the Role of the Hairless Gene
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 5-2006 Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene Yutao Liu University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Liu, Yutao, "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino- like Mouse Models: Tracking the Role of the Hairless Gene. " PhD diss., University of Tennessee, 2006. https://trace.tennessee.edu/utk_graddiss/1824 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Yutao Liu entitled "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences. Brynn H. Voy, Major Professor We have read this dissertation and recommend its acceptance: Naima Moustaid-Moussa, Yisong Wang, Rogert Hettich Accepted for the Council: Carolyn R.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Learning from Cadherin Structures and Sequences: Affinity Determinants and Protein Architecture
    Learning from cadherin structures and sequences: affinity determinants and protein architecture Klára Fels ıvályi Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Klara Felsovalyi All rights reserved ABSTRACT Learning from cadherin structures and sequences: affinity determinants and protein architecture Klara Felsovalyi Cadherins are a family of cell-surface proteins mediating adhesion that are important in development and maintenance of tissues. The family is defined by the repeating cadherin domain (EC) in their extracellular region, but they are diverse in terms of protein size, architecture and cellular function. The best-understood subfamily is the type I classical cadherins, which are found in vertebrates and have five EC domains. Among the five different type I classical cadherins, the binding interactions are highly specific in their homo- and heterophilic binding affinities, though their sequences are very similar. As previously shown, E- and N-cadherins, two prototypic members of the subfamily, differ in their homophilic K D by about an order of magnitude, while their heterophilic affinity is intermediate. To examine the source of the binding affinity differences among type I cadherins, we used crystal structures, analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and electron paramagnetic resonance (EPR) studies. Phylogenetic analysis and binding affinity behavior show that the type I cadherins can be further divided into two subgroups, with E- and N-cadherin representing each. In addition to the affinity differences in their wild-type binding through the strand-swapped interface, a second interface also shows an affinity difference between E- and N-cadherin.
    [Show full text]
  • Acceleration in the DNA Methylation Age in Breast Cancer Tumours from Very Young Women Sara S
    www.nature.com/scientificreports OPEN Acceleration in the DNA methylation age in breast cancer tumours from very young women Sara S. Oltra1, Maria Peña-Chilet1, Kirsty Flower2, María Teresa Martinez1, Elisa Alonso3, Octavio Burgues3, Ana Lluch1,4, James M. Flanagan 2 & Gloria Ribas1,4* Breast cancer in very young women (≤35 years; BCVY) presents more aggressive and complex biological features than their older counterparts (BCO). Our aim was to evaluate methylation diferences between BCVY and BCO and their DNA epigenetic age. EPIC and 450k Illumina methylation arrays were used in 67 breast cancer tumours, including 32 from BCVY, for methylation study and additionally we analysed their epigenetic age. We identifed 2 219 CpG sites diferently-methylated in BCVY vs. BCO (FDR < 0.05; β-value diference ± 0.1). The signature showed a general hypomethylation profle with a selective small hypermethylation profle located in open-sea regions in BCVY against BCO and normal tissue. Strikingly, BCVY presented a signifcant increased epigenetic age-acceleration compared with older women. The afected genes were enriched for pathways in neuronal-system pathways, cell communication, and matrix organisation. Validation in an independent sample highlighted consistent higher expression of HOXD9, and PCDH10 genes in BCVY. Regions implicated in the hypermethylation profle were involved in Notch signalling pathways, the immune system or DNA repair. We further validated HDAC5 expression in BCVY. We have identifed a DNA methylation signature that is specifc to BCVY and have shown that epigenetic age-acceleration is increased in BCVY. Breast cancer (BC) is the most common malignancy in women worldwide1. Approximately 6.6% of BCs are diag- nosed in women aged 40 or younger, and of all cancers diagnosed in this age group, 40% are BCs; the average risk of developing BC by age 40 is one in 1732 and unfortunately, they are not included in mammography screening programmes.
    [Show full text]
  • Detection of Somatic Variants from Genomic Data and Their Role in Neurodegenerative Diseases
    Detection of somatic variants from genomic data and their role in neurodegenerative diseases Irene Lobón García Aquesta tesi doctoral està subjecta a la llicència Reconeixement 4.0. Espanya de Creative Commons. Esta tesis doctoral está sujeta a la licencia Reconocimiento 4.0. España de Creative Commons. This doctoral thesis is licensed under the Creative Commons Attribution 4.0. Spain License. Memoria presentada por Irene Lobón García para optar al grado de doctora por la Universidad de Barcelona Programa de Doctorado en Biomedicina Tesis realizada en el Instituto de Biología Evolutiva (CSIC-UPF) Detection oF somatic variants From genomic data and their role in neurodegenerative diseases Irene Lobón García Eduardo Soriano García Tomàs Marquès Bonet A mi Familia, “La paciencia es la madre de la ciencia” ReFranero español Acknowledgements De estos cinco años me llevo innumerables enseñanzas. Por supuesto muchas en lo profesional, pero incluso más en lo personal. Esta tesis ha sido un trabajo en grupo y sin el apoyo y ayuda de mucha gente hubiese sido imposible. En primer lugar, quiero agradecer a Eduardo su conFianza todos estos años y sobre todo el haberme introducido con sus proyectos en el tema que ahora me apasiona. También a Tomàs por aceptarme en su grupo como estudiante de máster y después hacer lo posible para que me quedase de alguna manera en el grupo. También por introducirme en el consorcio que ha sido fundamental para mi trabajo y porque nunca hubiese salido de mí pedir una estancia en Harvard. Esta experiencia solo ha sido posible gracias a vosotros. Los comienzos Fueron duros, después de tantos años de aprendizaje guiado el salto a la investigación es diFícil.
    [Show full text]
  • Discovery of an O-Mannosylation Pathway Selectively Serving Cadherins and Protocadherins
    Discovery of an O-mannosylation pathway selectively serving cadherins and protocadherins Ida Signe Bohse Larsena,1, Yoshiki Narimatsua,1, Hiren Jitendra Joshia,1, Lina Siukstaitea, Oliver J. Harrisonb, Julia Braschb, Kerry M. Goodmanb, Lars Hansena, Lawrence Shapirob,c,d, Barry Honigb,c,d,e, Sergey Y. Vakhrusheva, Henrik Clausena, and Adnan Halima,2,3 aDepartment of Cellular and Molecular Medicine, Faculty of Health Sciences, Copenhagen Center for Glycomics, University of Copenhagen, DK-2200 Copenhagen, Denmark; bDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032; cZuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10032; dDepartment of Systems Biology, Columbia University, New York, NY 10032; and eHoward Hughes Medical Institute, Columbia University, New York, NY 10032 Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved September 6, 2017 (received for review May 22, 2017) The cadherin (cdh) superfamily of adhesion molecules carry muscular dystrophies that have been designated α-dystroglyca- O-linked mannose (O-Man) glycans at highly conserved sites nopathies because deficient O-Man glycosylation of α-DG dis- localized to specific β-strands of their extracellular cdh (EC) domains. rupts the interaction between the dystrophin glycoprotein complex These O-Man glycans do not appear to be elongated like O-Man and the ECM (7–9). Several studies have also implicated de- glycans found on α-dystroglycan (α-DG), and we recently demon- ficiency of POMT2 with E-cdh dysfunction (10–12), although di- strated that initiation of cdh/protocadherin (pcdh) O-Man glycosyl- rect evidence for a role in glycosylation of cdhs and pcdhs is ation is not dependent on the evolutionary conserved POMT1/ missing.
    [Show full text]
  • Fibroblast-Derived Induced Pluripotent Stem Cells Show No Common Retroviral Vector Insertions
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Harvard University - DASH Fibroblast-Derived Induced Pluripotent Stem Cells Show No Common Retroviral Vector Insertions The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Varas, Florencio, Matthias Stadtfeld, Luisa de Andres-Aguayo, Nimet Maherali, Alessandro di Tullio, Lorena Pantano, Cedric Notredame, et al. 2009. Fibroblast-Derived Induced Pluripotent Stem Cells Show No Common Retroviral Vector Insertions. Stem Cells 27(2): 300-306. Published Version doi:10.1634/stemcells.2008-0696 Accessed February 18, 2015 8:46:59 PM EST Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4459933 Terms of Use This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn- 3:HUL.InstRepos:dash.current.terms-of-use#OAP (Article begins on next page) EMBRYONIC STEM CELLS/INDUCED PLURIPOTENT STEM CELLS Fibroblast-Derived Induced Pluripotent Stem Cells Show No Common Retroviral Vector Insertions FLORENCIO VARAS,a MATTHIAS STADTFELD,b LUISA DE ANDRES-AGUAYO,a NIMET MAHERALI,b ALESSANDRO DI TULLIO,a LORENA PANTANO,c CEDRIC NOTREDAME,c KONRAD HOCHEDLINGER,b THOMAS GRAFa,d aDifferentiation and Cancer and cBioinformatics Program, Center for Genomic Regulation and Pompeu Fabra University, Barcelona, Spain; bCancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Stem Cell Institute, Boston, Massachusetts, USA; dInstitucio´ Catalana de Recerca i Estudis Avanc¸ats Key Words.
    [Show full text]
  • SH3PXD2A (SH3 and PX Domains 2A)
    SH3PXD2A (SH3 and PX domains 2A) The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Li, Carman Man-Chung and Tyler Jacks. “SH3PXD2A (SH3 and PX Domains 2A).” Atlas of Genetics and Cytogenetics in Oncology and Haematology 6 (2016): 326-330 © 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology As Published http://dx.doi.org/10.4267/2042/62941 Publisher INIST-CNRS Version Final published version Citable link http://hdl.handle.net/1721.1/116550 Terms of Use Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 Detailed Terms http://creativecommons.org/licenses/by-nc-nd/2.0/ Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Gene Section Review SH3PXD2A (SH3 and PX domains 2A) Carman Man-Chung Li, Tyler Jacks David H. Koch Institute for Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. [email protected] Published in Atlas Database: August 2015 Online updated version : http://AtlasGeneticsOncology.org/Genes/SH3PXD2AID45995ch10q24.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62941/08-2015-SH3PXD2AID45995ch10q24.pdf DOI: 10.4267/2042/62941 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology Abstract Transcription The full-length SH3PXD2A transcript is 11264 nt in The TKS5 protein, encoded by the gene length. Multiple TKS5 isoforms arise as a result of SH3PXD2A, is a scaffolding protein essential for the alternative mRNA splicing involving exons 7 and formation of podosomes and invadopodia in 10, and alternative use of transcription start sites.
    [Show full text]
  • A Protocol for Constructing Gene Targeting Vectors: Generating Knockout Mice for the Cadherin Family and Beyond
    PROTOCOL A protocol for constructing gene targeting vectors: generating knockout mice for the cadherin family and beyond Sen Wu1, Guoxin Ying2, Qiang Wu2 & Mario R Capecchi1,2 1Howard Hughes Medical Institute and 2Department of Human Genetics, University of Utah, Salt Lake City, Utah 84112, USA. Correspondence should be addressed to M.R.C. ([email protected]). Published online 29 May 2008; doi:10.1038/nprot.2008.70 s We describe here a streamlined procedure for targeting vector construction, which often is a limiting factor for gene targeting (knockout) technology. This procedure combines various highly efficient recombination-based cloning methods in bacteria, consisting of three steps. First step is the use of Red-pathway-mediated recombination (recombineering) to capture a genomic fragment into a Gateway-compatible vector. Second, the vector is modified by recombineering to include a positive selection gene neo,fromavariety natureprotocol / of modular reagents. Finally, through a simple in vitro Gateway recombination, the modified genomic fragment is switched into a m o c vector that contains negative selection cassettes, as well as unique sites for linearization. To demonstrate the usefulness of this . e r protocol, we report targeted disruptions of members of the cadherin gene family, focusing on those that have not been previously u t B a studied at the molecular genetic level. This protocol needs 2 weeks to construct a targeting vector, and several vectors can be n . easily handled simultaneously using common laboratory setup. w w w / / : p t INTRODUCTION t h Gene targeting, the use of homologous recombination in mouse this procedure is reduced when used for generating large DNA p 1–5 19,20 u embryonic stem (ES) cells to modify mouse genes precisely , constructs, required for gene targeting vector construction .
    [Show full text]
  • Long Noncoding RNA SH3PXD2A-AS1 Promotes
    Int. J. Biol. Sci. 2021, Vol. 17 1979 Ivyspring International Publisher International Journal of Biological Sciences 2021; 17(8): 1979-1994. doi: 10.7150/ijbs.58422 Research Paper Long noncoding RNA SH3PXD2A-AS1 promotes colorectal cancer progression by regulating p53- mediated gene transcription Pingfu Hou1,2,3*, Tian Lin1,2,3*, Sen Meng1,2,3*, Meilin Shi1, Fang Chen1, Tao Jiang1,4, Zhongwei Li1,2,3, Minle Li1,2,3, Sufang Chu1,2,3, Junnian Zheng2,3, Jin Bai1,2,3 1. Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. 2. Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. 3. Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. 4. Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. *These authors contributed equally to this work. Corresponding authors: Jin Bai, Cancer Institute, Xuzhou Medical University. 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China. Phone: 86-516-85582530; E-mail: [email protected]. Junnian Zheng, Cancer Institute, Xuzhou Medical University. 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China. E-mail: [email protected]. © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2021.01.20; Accepted: 2021.03.11; Published: 2021.05.11 Abstract Long non-coding RNAs (lncRNAs) play key roles in various human cancers. We aimed to determine the key lncRNAs mediating colorectal cancer (CRC) progression.
    [Show full text]
  • WO 2016/040794 Al 17 March 2016 (17.03.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/040794 Al 17 March 2016 (17.03.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12N 1/19 (2006.01) C12Q 1/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C12N 15/81 (2006.01) C07K 14/47 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/049674 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 11 September 2015 ( 11.09.201 5) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/050,045 12 September 2014 (12.09.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: WHITEHEAD INSTITUTE FOR BIOMED¬ DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, ICAL RESEARCH [US/US]; Nine Cambridge Center, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Cambridge, Massachusetts 02142-1479 (US).
    [Show full text]